Soheil Meshinchi

Appointments and Affiliations

 
 
Fred Hutchinson Cancer Research Center
Pediatric Hematology and Oncology
Clinical Research
Associate Member
Seattle Children's Hospital
Pediatric Hematology and Oncology
Pediatric Oncology/ Stem Cell Transplantation
Associate Professor and Attending Physican
University of Washington
Pediatric Hematology and Oncology
Pediatric Hematology/ Stem Cell Transplantation
Associate Professor
Professional Headshot of Soheil  Meshinchi

Mailing Address

Fred Hutchinson Cancer Research Center
Clinical Research Division
1100 Fairview Ave. N.
Mail Stop D5-380
Seattle, Washington 98109
United States

Contact

Phone: (206) 667-4077
Fax: (206) 667-4310
smeshinc@fhcrc.org

Degrees

Fellowship Training, University of Washington, Pediatic Hematology and Oncology, 2000.
Fellowship Training, Fred Hutchinson Cancer Research Center, Pediatic Hematology and Oncology, 2000.
Residency Training, Johns Hopkins Hospitals, Pediatrics, 1997.
M.D., Wayne State University, 1994.
Ph.D., University of Michigan, Pharmacology/Protein Biochemistry, 1990.

Research Interests

A. Clinical Expertise:
- Identification and therapy of high-risk leukemias
- Management of post transplant relapse in childhood leukemias
- Stem cell transplantation in leukemias
- Therapy of relapsed AML
- Targeted therapy in pediatric AML

B. Laboratory Interests:

Genomic alterations in AML and their role in the Pathogenesis of AML
- Biologic implications of disease associated mutations in AML
- Prelavence and clinical significance of FLT3 and other RTK mutations in AML
- Biologic consequence of RTK mutations in normal and malignant hematopoiesis

TARGET Initiative
- TARGET (Therapeutically Applicable Research to Generate Effective Treatments) Initiative, seeks to identify valid therapeutic targets so that new, more effective treatments can be developed for children with cancer. AML is one of the 5 diseases selected for comprehensive mutli-platform genomic and epi-genomic evaluation to identify biomarkers associated with disease outcome as well those who are viable candidates for targeted therapy. As part of this initiative, several hundred specimens from children with AML will undergo whole genome, whole transcriptome and exome capture sequencing to identify disease associated alterations. Upstream gene, transcript, methylation and miRNA profiling will be performed for integration with the sequencing data. Identified biomarkers will be rapidly validated and translated into clinical application.

Identification of novel markers of high risk disease in AML.
- Using state of the art molecular biologic techniques putative high risk markers are being identified and validated in a large cohort of pediatric and adult AML patients. This information will be used to create a patient-specific risk profile to be used in treatment assignment

Minimal Residual Disease (MRD) as a marker of high-risk disease in Pediatric AML
- Evaluation of flow cytometric evidence of MRD and its correlation with outcome
- Evaluation of molecular evidence of MRD and correlation with outcome
- Stem Cell origin of myeloid leukemias and role of RTK mutations in the evolution of AML
- Role of activating mutations of the signal transduction pathway in myeloid malignancies

Languages

Reading, Writing, Speaking

Farsi: Functional, Functional, Fluent

Memberships

American Society of Clinical Oncology
American Society of Hematology
Children's Oncology Group Myeloid Disease Committee
Childrens Oncology Group

Honors and Awards

Jose Carrera's International Leukemia Fellow, Jose Carrera's Leukemia Foundation, Fred Hutchinson Cancer Research Center, Molecular Pathogenesis of FLT3 Mutations in AML
Child Health Research Center Scholar, National Institutes of Health (NIH), University of Washington
COG Young Investigator Award, Childrens Oncology Group

Previous Positions

Acting Instructor, Fred Hutchinson Cancer Research Center
Assistant Professor and Attending Physician, Children's Hospital and Regional Medical Center, Pediatric Hematology and Oncology
Assistant Member, Fred Hutchinson Cancer Research Center, Clinical Research Division, Pediatric Oncology/Stem Cell Transplantation
Assistant Professor, University of Washington, School of Medicine, Pediatrics, Pediatric Hematology and Oncology, Stem Cell Transplantation

Funding

  • National Institutes of Health (NIH): R01, Administrative Supplement to current R01, Biology and Prognostic Implications of FLT3 Mutations in AML, 2009 to 2010.
  • Children's Oncology Group: Molecular Assessment of Minimal Risk in Acute Promyelocytic Leukemia, 2009 to 2010.
  • National Institutes of Health (NIH): TARGET Supplement to the Children's Oncology Group Chair's Grant, 2009 to 2011.
  • Fred Hutchinson Cancer Research Center and National Institute of Health: Pilot Study Single Cell Genomic Profiling in Cancer, 2009 to 2010.
  • Fred Hutchinson Cancer Research Center and CCEH: Pilot Study Validating Susceptibility Genes for Acute Myeloid Leukemia, 2009 to 2010.
  • Children's Oncology Group: COG Scientific Committee Chair, 2009 to 2010.
  • National Cancer Institute/ National Children's Cancer Foundation: Biomarkers for Risk Identification and Risk-Based Therapy in Pediatric AML, 2008 to 2010.
  • Seattle Children's: Alterations of DNA Repair Pathway in Regulating Homologous Recombination in AML, 2008 to 2010.
  • Seattle Children's: Biologic and Clinical Implications of a s-SHIP Expression in Pediatric Leukemias, 2007 to 2010.
  • National Institutes of Health (NIH): RO-1, Biology and Prognostic Implications of FLT3 Mutations in AML, 2005 to 2010.
  • National Institutes of Health (NIH): R-21, Accurate Prediction of Early Relapse in Pediatric AML, 2004 to 2006.
  • Children's Oncology Group: COG Translational Research Award, 2004 to 2006.
  • National Institutes of Health (NIH): R-21, Prognostic Implications of FLT3 Mutations in AML, 2003 to 2006.
  • Children's Oncology Group: COG Young Investigator Award, 2001 to 2002.
  • NIH/University of Washington: Child Health Research Center Award, 2000 to 2002.
  • Jose Carreras Leukemia Foundation: Jose Carrera's International Leukemia Foundation, Young Investigator Award, 2000 to 2003.
  • National Institutes of Health/FHCRC: K-12 Translational Research Award, 2000 to 2002.

 

Recent Publications

2014
2013
Meshinchi, S.  2013.  Hematopoietic cell transplantation in high-risk childhood acute myelogenous leukemia.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(7):1002-3.
2012
Meshinchi, S, Hunger SP, Aplenc R, Adamson PC, Jessup MJ.  2012.  Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(6):1547-54. Abstract
Carpenter, PA, Meshinchi S, Davies SM.  2012.  Transplantation for AML in children.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 18(1 Suppl):S33-9.